Schroetter Syndrome: Effort-Induced Upper Extremity DVT Explained
Indunil Karunarathna, Founder of Uva Clinical Research Lab (UCRL), posted on LinkedIn:
”Schroetter Syndrome Effort Induced Upper Extremity Deep Vein Thrombosis
Paget-Schroetter syndrome (PSS), also known as “effort thrombosis,” represents a primary form of upper extremity deep vein thrombosis (UEDVT) typically arising in young, healthy, and active individuals following strenuous or repetitive upper limb exertion.
Recognized as the venous subtype of thoracic outlet syndrome (TOS), PSS occurs due to mechanical compression of the subclavian vein within the costoclavicular space, often potentiated by structural anomalies such as cervical ribs, hypertrophied scalene muscles, or aberrant ligamentous insertions. The pathophysiology integrates Virchow’s triad, with endothelial trauma, venous stasis, and hypercoagulability converging to precipitate thrombosis.
Clinically, PSS presents with sudden upper extremity swelling, pain, heaviness, and cyanosis, often following athletic or occupational activity. Diagnosis requires high clinical suspicion and confirmation with duplex ultrasonography, venography, or advanced cross-sectional imaging, while laboratory investigations may identify concomitant thrombophilic disorders.
Management strategies emphasize multimodal therapy: immediate anticoagulation, catheter-directed thrombolysis (CDT) or pharmacomechanical thrombectomy for clot clearance, and surgical thoracic outlet decompression to correct the underlying anatomical cause. Long-term outcomes are optimized by interdisciplinary collaboration involving vascular surgeons, radiologists, internists, and rehabilitation specialists.
Despite advances in endovascular and surgical techniques, controversies remain regarding timing of decompression, duration of anticoagulation, and management of chronic venous occlusion. With appropriate treatment, recanalization rates of 75–90% are achievable, preventing long-term complications such as recurrent thrombosis, pulmonary embolism, and postthrombotic syndrome.
Future research should focus on refining minimally invasive strategies, optimizing patient selection for surgical intervention, and developing preventive approaches for high-risk athletic populations.”
Read the full article here.
Author: Indunil Karunarathna

Stay updated with Hemostasis Today.
-
Feb 23, 2026, 13:53Rare Diseases, Plasma-Derived Medicines and the Elephant in the Room – Part 1
-
Feb 23, 2026, 13:02Deepak Yadav: What 2025 Evidence Tells Us About Stroke Care
-
Feb 23, 2026, 12:55Radoslaw Kaczmarek: Will AAV Gene Therapy for Hemophilia Trigger Tumorigenesis?
-
Feb 23, 2026, 12:46Heghine Khachatryan: More Granular Risk Stratification Framework for PE from The New 2026 AHA/ACC Guideline
-
Feb 23, 2026, 12:37Reza Shojaei: EU’s Critical Medicines Act and Plasma Resilience
-
Feb 23, 2026, 12:32Anirban Sen Gupta: Emily Mihalko Highlights PlateChek at MTEC
-
Feb 23, 2026, 12:25Ryan Williams: Excellent Highlights on The Heterogeneity of PRP Preparation
-
Feb 23, 2026, 12:10Peter Libby: hsCRP May Select Patients Who Can Benefit From Statins or Anti-inflammatory Therapy
-
Feb 23, 2026, 12:02Marios Georgakis: An Unprecedented for An Antithrombotic Therapy from OCEANIC-STROKE Trial